ag-1296 has been researched along with Leukemia, Myeloid in 5 studies
6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, dose-response cytotoxic assays were performed with AG1295, a tyrosine kinase inhibitor active against FLT3, on primary blasts from patients with AML." | 1.31 | A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. ( Garrett, E; Levis, M; Small, D; Smith, BD; Tse, KF, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagrintseva, K | 1 |
| Schwab, R | 1 |
| Kohl, TM | 1 |
| Schnittger, S | 1 |
| Eichenlaub, S | 1 |
| Ellwart, JW | 1 |
| Hiddemann, W | 1 |
| Spiekermann, K | 1 |
| Scholl, S | 1 |
| Kirsch, C | 1 |
| Böhmer, FD | 1 |
| Klinger, R | 1 |
| Levis, M | 1 |
| Tse, KF | 1 |
| Smith, BD | 1 |
| Garrett, E | 1 |
| Small, D | 1 |
| Grundler, R | 1 |
| Thiede, C | 1 |
| Miething, C | 1 |
| Steudel, C | 1 |
| Peschel, C | 1 |
| Duyster, J | 1 |
| Kajiguchi, T | 1 |
| Chung, EJ | 1 |
| Lee, S | 1 |
| Stine, A | 1 |
| Kiyoi, H | 1 |
| Naoe, T | 1 |
| Levis, MJ | 1 |
| Neckers, L | 1 |
| Trepel, JB | 1 |
5 other studies available for ag-1296 and Leukemia, Myeloid
| Article | Year |
|---|---|
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Divi | 2004 |
Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Humans; Intracellular Signaling Peptide | 2004 |
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Huma | 2001 |
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Topics: Acute Disease; Amino Acid Substitution; Animals; Cell Division; Cell Line; Codon; DNA-Binding Protei | 2003 |
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Topics: Active Transport, Cell Nucleus; Acute Disease; Animals; beta Catenin; Cell Line, Tumor; fms-Like Tyr | 2007 |